Safety profile of treatment with greenlight versus Thulium Laser for benign prostatic hyperplasia

Arch Ital Urol Androl. 2023 Feb 22;95(1):11101. doi: 10.4081/aiua.2023.11101.

Abstract

Objective: The major strengths of surgical treatment of benign prostatic hyperplasia with laser are reduced morbidity compared to endoscopic resection. No studies analysed the different risk of intra/peri-operative events between patients undergoing Thulium and GreenLight procedures.

Materials and methods: We retrospectively reviewed 100 consecutive cases undergoing GreenLight vaporization and Thulium procedures performed during the learning curve of two expert endoscopic surgeons. Pre-operative data, intra and post-operative events at 90 days were analysed.

Results: Patients on antiplatelet/anticoagulant therapy were pre-dominant in the Green group (p < 0.0001). Rates of blood transfusion (p < 0.0038), use of resectoscope (p < 0.0086), and transient stress urinary incontinence were statistically higher in the Thulium group. On the contrary conversions to TURP (p < 0.023) were more frequent in GreenLight patients. Readmissions were more frequently necessary in GreenLight group (24%) vs. Thulium group (26.6%). The overall complication rate in GreenLight and Thulium groups were 31% and 53% respectively; Clavien 3b complications were 13% in Thulium patients versus 1% in GreenLight patients.

Conclusions: GreenLight and Thulium treatments show similar safety profiles. Randomized controlled trial are needed to better clarify the rate of major complications in Thulium group, and the incidence of post-operative storage symptoms in these patients' populations.

MeSH terms

  • Humans
  • Laser Therapy* / adverse effects
  • Laser Therapy* / methods
  • Lasers
  • Male
  • Prostatic Hyperplasia* / complications
  • Retrospective Studies
  • Thulium / therapeutic use
  • Transurethral Resection of Prostate* / adverse effects
  • Transurethral Resection of Prostate* / methods
  • Treatment Outcome

Substances

  • Thulium